# China NMPA Drug Inspection - Beijing Shengtianfang Medical Technology Research Institute - Herbal Blood Sugar Lowering

Source: https://www.globalkeysolutions.net/records/china_drug_inspection/beijing-shengtianfang-medical-technology-research-institute/3fb5a888-db77-4488-b096-019e306684d0/
Source feed: China

> China NMPA drug inspection for Beijing Shengtianfang Medical Technology Research Institute published December 27, 2021. Drug: Herbal Blood Sugar Lowering. On December 27, 2021, the Hubei Provincial Drug Administration published Issue 3 of its 2021 Quality Bulletin, reporting

---

## Details

- Record Type: CHINA_DRUG_INSPECTION
- Title: Hubei Province Drug Quality Bulletin (Issue 3, 2021)
- Company Name: Beijing Shengtianfang Medical Technology Research Institute
- Publication Date: 2021-12-27
- Drug Name: Herbal Blood Sugar Lowering
- Inspection Finding: Glibenclamide was detected, but gliclazide, glimepiride, and repaglinide were not detected.
- Action Taken: Necessary control measures such as sealing, seizing, suspending sales, and recalling products shall be implemented, and production, operation, and use units shall be investigated and dealt with in accordance with relevant laws and regulations; if a crime is suspected, the case shall be promptly transferred to the public security organs for criminal prosecution.
- Summary: On December 27, 2021, the Hubei Provincial Drug Administration published Issue 3 of its 2021 Quality Bulletin, reporting that 33 batches of drugs failed to meet national quality standards. The inspection covered various production, distribution, and healthcare units across the province. Involved companies include Hubei Shenlongyuan Pharmaceutical Co., Ltd., Hubei Phoenix Baiyunshan Pharmaceutical, and Beijing Tongrentang (Bozhou) Pharmaceutical Co., Ltd., among others. Main violations included failures in appearance, microscopic identification, and incorrect levels of active ingredients. Several traditional Chinese medicine products exceeded limits for ash content and impurities, while some manufacturers were found operating with expired licenses. Critically, one product, 'Baicao Jiangtang,' was identified as counterfeit due to the presence of undeclared chemical additives. These evaluations were conducted under the regulatory framework of the Chinese Pharmacopoeia (2015 and 2020 editions) and Hubei provincial standards for medical preparations. Required regulatory actions include the immediate sealing, seizure, and recall of non-compliant products. The administration has also ordered thorough investigations and administrative penalties for the responsible entities. For cases involving counterfeit goods or untraceable sources, the matter will be referred to public security organs for criminal prosecution to ensure public medication safety.

Company: https://www.globalkeysolutions.net/companies/beijing-shengtianfang-medical-technology-research-institute/dd9e55c9-9a51-4ebe-aed7-348228fd794c/